Stony Brook Heart Institute Delivers World’s First Commercial Plozasiran Treatment for Patients with Rare Lipid Disease

STONY BROOK, NY, December 30, 2025 - Stony Brook Heart Institute's Center for Advanced Lipid Management has achieved a historic global milestone, becoming the first center in the world to administer a commercial dose of plozasiran, the newly approved RNA-interference therapy for Familial Chylomicronemia Syndrome (FCS).

FCS is an ultra-rare condition marked by extreme triglyceride levels, often 10 to 100 times above normal, leading to recurrent and severe pancreatitis. An estimated 6,500 people in the United States are affected by genetic or clinical FCS. Plozasiran, a newly FDA-approved RNAi therapy targeting apolipoprotein C-III, demonstrated profound and sustained triglyceride reductions and fewer pancreatitis episodes in the PALISADE Phase 3 trial, representing a transformative advance for patients who previously had no effective treatment options.

"This is a historic moment for patients with FCS everywhere," said Dr. Tahmid Rahman, Co-Director of the Center for Advanced Lipid Management at the Stony Brook Heart Institute. "Our early research involvement and specialized, referral-level clinical infrastructure allowed us to deliver this therapy within days of FDA approval."

"Stony Brook's Advanced Lipid Management Center combines specialized diagnostic expertise with coordinated, precision care to rapidly identify rare and complex lipid disorders and deliver state-of-the-art, disease-modifying therapies such as plozasiran," said Dr. On Chen, Co-Director of the Center for Advanced Lipid Management at the Stony Brook Heart Institute. "The Center of Excellence program specializes in genetic and rare lipid disorders, including familial hypercholesterolemia, elevated lipoprotein(a), Familial Chylomicronemia Syndrome, and severe inherited hypertriglyceridemia. The program also provides comprehensive care for patients with coronary artery disease, prior heart attack or stroke and peripheral arterial disease. For patients focused on prevention, the program offers advanced cardiovascular risk assessment using state-of-the-art imaging and testing to deliver tailored, early intervention strategies."

Patients also benefit from advanced, emerging and transformative therapies, including novel biologics, RNA-based treatments like plozasiran, and clinical trials for individuals whose cholesterol or triglycerides remain uncontrolled with standard therapies-positioning Stony Brook Medicine as a regional and national leader in advanced lipid care.

"This milestone further reinforces Stony Brook Medicine's role as a destination center for patients and referring physicians seeking comprehensive evaluation and access to the most advanced therapies through our Heart Institute's Center of Excellence programs," added Hal Skopicki, MD, PhD, Co-Director of the Stony Brook Heart Institute and Ambassador Charles A. Gargano Chair of Cardiology.

For more information or to schedule an appointment with the Center for Advanced Lipid Management, visit https://heart.stonybrookmedicine.edu/LipidProgram.

About Stony Brook Heart Institute:

Stony Brook Heart Institute is located within Stony Brook University Hospital, part of Long Island's premier university-based medical center. The Heart Institute offers a comprehensive, multidisciplinary program for the prevention, diagnosis, and treatment of cardiovascular disease, integrating clinical excellence with discovery and innovation, bringing together board-certified cardiologists, cardiothoracic and vascular surgeons, and advanced practice clinicians alongside nurses, therapists, technologists and scientists. The Heart Institute delivers state-of-the-art interventional and surgical capabilities through 24-hour cardiac catheterization laboratories and advanced surgical suites while advancing the science of cardiovascular medicine through translation and clinical research. To learn more, visit www.heart.stonybrookmedicine.edu.